Antibody

In-Vivo Micro Computed Tomography to Account for over 3/4th of the global Market throughout the Analysis Period, States Future Market Insights

Retrieved on: 
Wednesday, June 1, 2022
Ex vivo, Greater New York, Dentistry, List of life sciences, Growth, Antibody, ESOMAR, Industry, Greater New York Chamber Of Commerce, Plant, Product type, CAGR, Commerce, Medical device, Food, Geology

NEWARK, Del., June 1, 2022 /PRNewswire/ -- The Micro Computed Tomography Market revenues were estimated at US$ 190.3 Mn in 2021 and is anticipated to grow at a CAGR of 11.3% from 2022-2032, according to a recently published Future Market Insights report. By the end of 2032, the market is expected to reach US$ 608.7 Mn. In-Vivo Micro Computed Tomography to Register an Absolute Dollar Opportunity of US$ 346 Mn.

Key Points: 
  • Future Market Insights, in its new offering, presents an unbiased analysis of the Micro Computed Tomography Market, presenting historical market data (2017-2021) and forecast statistics for the period of 2022-2032.
  • Home Rehabilitation Services Market - The global home rehabilitation services market totaled US$ 84.1 Bn in 2021.
  • Disposable Blood Pressure Cuffs Market - The disposable blood pressure cuffs market is projected to acquire a CAGR of 12.3% from 2022 to 2032.
  • Future Market Insights (ESOMAR certified market research organization and a member of the Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market.

In-Vivo Micro Computed Tomography to Account for over 3/4th of the global Market throughout the Analysis Period, States Future Market Insights

Retrieved on: 
Wednesday, June 1, 2022
Ex vivo, Greater New York, Dentistry, List of life sciences, Growth, Antibody, ESOMAR, Industry, Greater New York Chamber Of Commerce, Plant, Product type, CAGR, Commerce, Medical device, Food, Geology

NEWARK, Del., June 1, 2022 /PRNewswire/ -- The Micro Computed Tomography Market revenues were estimated at US$ 190.3 Mn in 2021 and is anticipated to grow at a CAGR of 11.3% from 2022-2032, according to a recently published Future Market Insights report. By the end of 2032, the market is expected to reach US$ 608.7 Mn. In-Vivo Micro Computed Tomography to Register an Absolute Dollar Opportunity of US$ 346 Mn.

Key Points: 
  • Future Market Insights, in its new offering, presents an unbiased analysis of the Micro Computed Tomography Market, presenting historical market data (2017-2021) and forecast statistics for the period of 2022-2032.
  • Home Rehabilitation Services Market - The global home rehabilitation services market totaled US$ 84.1 Bn in 2021.
  • Disposable Blood Pressure Cuffs Market - The disposable blood pressure cuffs market is projected to acquire a CAGR of 12.3% from 2022 to 2032.
  • Future Market Insights (ESOMAR certified market research organization and a member of the Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market.

Harbour BioMed Reports the Latest Progress of Next-Generation Fully Human Heavy-chain Antibody HBM4003 with Unique Treg Depletion Mechanism

Retrieved on: 
Wednesday, June 1, 2022
SD, Phases of clinical research, ADCC, View, Lymphocytopenia, Pharmacokinetics, Squamous cell carcinoma, Company, CMO, Antibody opsonization, Society, American Society of Clinical Oncology, Neoplasm, Harbor, Toxicity, ORR, Melanoma, HKEX, RCC, DLS, ASCO, CTLA4, Therapy, Multimedia, Leukopenia, 2021 Essex County Council election, Trae tha Truth, DCR, HCC, Trial of the century, Patient, Antibody, MOA, PR, H2L2, Renal cell carcinoma, Rash, Pharmaceutical industry, Medical imaging, Vaccine, Regulatory T cell, Safety, Tolerability

The Treg depleting activity of HBM4003 offers a potential for clinical efficacy in indications hitherto unaddressed by first generation CTLA4 inhibitors.

Key Points: 
  • The Treg depleting activity of HBM4003 offers a potential for clinical efficacy in indications hitherto unaddressed by first generation CTLA4 inhibitors.
  • HBM4003 is a fully human anti-CTLA-4 monoclonal heavy chain only antibody (HCAb) generated from Harbour Mice.
  • The Company's proprietary antibody technology platforms Harbour Micegenerate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format.
  • Integrating Harbour Mice, HBICE with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.

Codagenix Receives FDA Clearance of Investigational New Drug Application for Live-Attenuated, Intranasal RSV Vaccine Candidate CodaVax™-RSV

Retrieved on: 
Wednesday, June 1, 2022
Hospital, World Health Organization, Entrepreneurship, Death, Adult, Stony Brook University, Research, Infection, National Academy of Sciences, Food, Primate, Genome, RSV, Ageing, Immunity, Investigational New Drug, National academy, Therapy, IND, Vaccine, FDA, National, Risk, Technology, COVID-19, Phenotype, Antibody, Public health, Antigen, Regulation of tobacco by the U.S. Food and Drug Administration, Cancer

FARMINGDALE, N.Y., June 1, 2022 /PRNewswire/ -- Codagenix Inc., a clinical-stage synthetic biology company with a rational virus design platform for viral vaccines and immuno-oncology therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for CodaVax™-RSV, an intranasal, live-attenuated vaccine candidate, for the prevention of respiratory syncytial virus (RSV) infection in healthy infants and toddlers. RSV is an acute respiratory infection that is the leading cause of hospitalization for young children.

Key Points: 
  • With this FDA clearance, the company plans to initiate a Phase 1 study of vaccine safety and immunogenicity against RSV in healthy children aged six months to five years.
  • Codagenix's CodaVax-RSV vaccine includes hundreds of strategic genomic modifications that slow viral replication, resulting in a genetically stable, attenuated vaccine virus that includes all RSV proteins as antigens.
  • "RSV causes incredible suffering to children and their families worldwide, and development of a pediatric RSV vaccine is a top World Health Organization priority.
  • "Unfortunately, previous live-attenuated RSV vaccine candidates were not well tolerated due to genetic instability and risk of reversion to wild type phenotype.

SAB Biotherapeutics Chief Operating Officer, Dr. Christoph Bausch, to Present at the Large Animal Genetic Engineering Summit

Retrieved on: 
Tuesday, May 31, 2022
Severe acute respiratory syndrome coronavirus 2, Immunotherapy, U.S. Securities and Exchange Commission, Nasdaq, Genetic engineering, Infection, Government, Antibody, Private Securities Litigation Reform Act, COVID-19, SAB, Research, Plasma, Probability, Forward-looking statement, TC, Technology, Degenerative disease, Twitter, Organ transplantation, Drug discovery, Cancer, Prospectus, GLOBE, Vaccine

SIOUX FALLS, S.D., May 31, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies without the need for human donors, today announced its participation at the Large Animal Genetic Engineering Summit (LAGE) taking place June 5-8, 2022, in Park City, Utah. SAB Chief Operating Officer, Dr. Christoph Bausch, will present as part of the summit’s “Gene Editing to Improve Human Health” track.

Key Points: 
  • SAB Chief Operating Officer, Dr. Christoph Bausch, will present as part of the summits Gene Editing to Improve Human Health track.
  • Additionally, he will discuss the potential that SABs novel immunotherapy platform has to expand into personalized medicine through the development of Transchromosomic (Tc) Goats.
  • SAB currently has multiple drug development programs underway and collaborations with the US government and global pharmaceutical companies.
  • Actual events and circumstances are difficult or impossible to predict, will differ from assumption and are beyond the control of SAB.

Biond Biologics Announces a Joint Poster Presentation With Sanofi at The ASCO 2022 Annual Meeting Presenting Pre-Clinical Translational Data of SAR444881 (BND-22)

Retrieved on: 
Tuesday, May 31, 2022
Myelocyte, Annual general meeting, VP, Enzyme, Tumor microenvironment, CD28, Sanofi, Patient, Poster, Phagocytosis, PD-1, Antibody, MHC, Society, American Society of Clinical Oncology, ILT2, Spatial planning, ILT3, Cell, Immunoglobulin G, Biomarker, ASCO, Escape Room, Protein, Cancer, LILRB1, Pharmaceutical industry, Vaccine, Serenate per 16 bionde

The poster presents pre-clinical translational data including potential patient enrichment biomarkers for SAR444881 (BND-22).

Key Points: 
  • The poster presents pre-clinical translational data including potential patient enrichment biomarkers for SAR444881 (BND-22).
  • The poster will be presented at:
    Abstract Title: Evaluation of pharmacodynamic and patient enrichment biomarkers for SAR444881, a first-in-class anti-ILT2 monoclonal antibody for cancer immunotherapy.
  • Leukocyte Ig-like receptor B1 (LILRB1), also known as immunoglobulin-like transcript 2 (ILT2), is an inhibitory receptor expressed on various immune cells.
  • "We previously demonstrated that SAR444881 has robust macrophage and lymphocyte-driven anti-tumor activity in in vitro and in vivo models.

argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized Myasthenia Gravis

Retrieved on: 
Tuesday, May 31, 2022
Autoantibody, Immunoglobulin G, Degenerative disease, Neuromuscular Disorders, SE, Acetylcholine receptor, Neonatal Fc receptor, Euronext, European Medicines Agency, Patient, MG, Antibody, EAMS, MHRA, Review, Muscle, Therapy, United Kingdom, PIM, Adult, FC, EMA, GMG, Communication, Autoimmune disease, IIP, Steroid, MAA, Pharmaceutical industry, Vaccine

The EAMS program offers early access to innovative medicines for patients who are experiencing a significant unmet medical need, before the MHRA approves a formal marketing authorization application (MAA) and prior to reimbursement.

Key Points: 
  • The EAMS program offers early access to innovative medicines for patients who are experiencing a significant unmet medical need, before the MHRA approves a formal marketing authorization application (MAA) and prior to reimbursement.
  • Despite currently available treatments, gMG patients in the UK face a significant disease burden and many struggle to manage the debilitating symptoms of this rare autoimmune disease.
  • We look forward to continued collaboration with the agency to make this innovative therapy available to UK patients as soon as possible.
  • Efgartigimod was previously granted a PIM designation by the MHRA in November 2021.

Alzheimer's Disease Treatment Global Market Report 2022 Featuring Major Players - Allergan, Eisai, Novartis, Pfizer, Merz Pharma, H. Lundbeck A/S Biogen, AstraZeneca and F. Hoffmann-La Roche - ResearchAndMarkets.com

Retrieved on: 
Monday, May 30, 2022
Health, Biotechnology, Dementia, Acetylcholine, Memantine, Disease, Amnesia, Antibody, AC, Cholinesterase, Investment, Acetylcholinesterase, BACE, Government, Novartis, Therapy, Merz Pharma, Association, Allergan, Alzheimer's Association, Cholinesterase inhibitor, Neurological disorder, Thought, AD, Social skills, Pfizer, BACE1, VTV, NMDA, Geriatrics, Neurology, Growth, Prevalence, Diagnosis, AstraZeneca, Medical device, Residential care, Pharmaceutical industry, Medical imaging, Alzheimer's disease

Major players in the alzheimer's disease treatment market are Allergan, Eisai Co. Ltd., Novartis AG, Pfizer Inc., Merz Pharma, H. Lundbeck A/S Biogen, AstraZeneca and F. Hoffmann-La Roche Ltd.

Key Points: 
  • Major players in the alzheimer's disease treatment market are Allergan, Eisai Co. Ltd., Novartis AG, Pfizer Inc., Merz Pharma, H. Lundbeck A/S Biogen, AstraZeneca and F. Hoffmann-La Roche Ltd.
  • The global alzheimer's disease treatment market consists of sales of drugs used to treat Alzheimer's disease.
  • Therefore, the increasing prevalence of Alzheimer's disease is expected to drive the growth of the global Alzheimer's disease treatment market.
  • Lack of techniques for diagnosing Alzheimer's disease (AD) is expected to limit the growth of the global Alzheimer's disease treatment market.

Concept Companies Leads Development Efforts on Second Phase for Lacerta Therapeutics in Alachua's Progress District

Retrieved on: 
Friday, May 27, 2022
Health, Education, Solution, Antibody, Therapy, CGMP, Architecture, Denton Road-Sparks Foundation Park Pond Bridge, Research, University, Industry, AAV, Life, Heel, Santa Fe College, Concept, Growth, CEO, GLOBE, Pharmaceutical industry, Lacerta

The site will be located adjacent to Lacerta Therapeutics' current location in Alachua, Florida, in Copeland Park, which Lacerta has occupied since 2020.

Key Points: 
  • The site will be located adjacent to Lacerta Therapeutics' current location in Alachua, Florida, in Copeland Park, which Lacerta has occupied since 2020.
  • The expansion into this second building will be primarily manufacture-focused, which will complement the first facility, which is geared toward research and development.
  • "We are excited to continue our relationship with Brian and his team at Concept Companies," said Dr. Edgar Rodriguez-Lebron, President & CEO of Lacerta Therapeutics.
  • "We are thrilled to be able to once again work with Lacerta Therapeutics as they continue to expand their operations," said Brian Crawford, Founder, Owner, and CEO of Concept Companies.

Bolt Biotherapeutics to Present Ex Vivo Data Characterizing the Myeloid Cell Landscape in Solid Tumors at ASCO 2022

Retrieved on: 
Friday, May 27, 2022
Company, Myelocyte, HER2, Neoplasm, Annual general meeting, U.S. Securities and Exchange Commission, Nasdaq, Tumor microenvironment, Poster, Patient, Antibody, Society, American Society of Clinical Oncology, ISAC, PD-L1, Immunology, Industry, Forward-looking statement, Safety, ASCO, Bolt, Security (finance), CEA, Immune system, Cancer, McCormick Place, Annual report, GLOBE, Vaccine

REDWOOD CITY, Calif., May 27, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that it will be presenting a poster at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held at McCormick Place in Chicago and virtually from June 3-7, 2022. The poster is titled “Characterization of tumor antigen expression and myeloid immune profiles to inform the development of immune-stimulating antibody conjugates (ISACs).”

Key Points: 
  • The data being presented at ASCO demonstrate that myeloid cells are consistently present in solid tumors.
  • Bolt researchers characterized the myeloid immune landscape of tumor microenvironments from five solid tumor types.
  • The data demonstrate that myeloid cells are present in all tested tumor microenvironments, including those with low T cell infiltration.
  • Bolt Biotherapeutics proprietary Boltbody Immune-stimulating Antibody Conjugates (ISACs) are designed to target tumor cells for elimination by the immune system.